Bladder cancer: Time for a rethink?

Oncology

Volumn 25, Issue 10, 2011, Pages

  Bryan, Richard T ^a   James, Nicholas D ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE;

ARTICLE; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER EPIDEMIOLOGY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CYSTECTOMY; HUMAN; MULTIMODALITY CANCER THERAPY; TRANSURETHRAL RESECTION;

EID: 80053630943     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Malmstrom PU. Bladder tumours: time for a paradigm shift? BJU Int. 107:1543-5.
2. Lotan Y, Kamat AM, Porter MP, et al. Key concerns about the current state of bladder cancer: a position paper from the Bladder Cancer Think Tank, the Bladder Cancer Advocacy Network, and the Society of Urologic Oncology. Cancer. 2009;115:4096-103.
3. Bryan RT Wallace DM. Have we abandoned the superficial in bladder cancer? Eur Urol. 2009;56:1091.
4. Riley GF, Potosky AL, Lubitz JD Kessler LG. Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care. 1995;33:828-41.
5. Ploeg M, Aben KK Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J Urol. 2009;27:289-93.
6. Bryan RT, Zeegers MP, Bird D, et al. 20-years of bladder cancer research in the West Midlands: a comparison of two large cohorts. J Urol. 2010;183:e196.
7. Wilby D, Thomas K, Ray E, et al. Bladder cancer: new TUR techniques. World J Urol. 2009;27:309-12.
8. Cauberg EC, de Bruin DM, Faber DJ, et al. A new generation of optical diagnostics for bladder cancer: technology, diagnostic accuracy, and future applications. Eur Urol. 2009;56:287-96.
9. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19:666-75.
10. Rodel C, Grabenbauer GG, Kuhn R, et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results.[see comment]. J Clin Oncol. 2002;20:3061-71.
11. Hayter CR, Paszat LF, Groome PA, et al. The management and outcome of bladder carcinoma in Ontario, 1982-1994. Cancer. 2000;89:142-51.
12. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.[see comment][erratum appears in N Engl J Med. 2003 Nov 6;349(19):1880].
13. N Engl J Med. 2003;349:859-66.
14. Konety BR Joslyn SA. Factors influencing aggressive therapy for bladder cancer: an analysis of data from the SEER program. J Urol. 2003;170:1765-71.
15. Jahnson S, Damm O, Hellsten S, et al. A population-based study of patterns of care for muscle-invasive bladder cancer in Sweden. Scand J Urol Nephrol. 2009;43:271-6.
16. Munro NP, Sundaram SK, Weston PM, et al. A 10-year retrospective review of a nonrandomized cohort of 458 patients undergoing radical radiotherapy or cystectomy in Yorkshire, UK. Int J Radiat Oncol Biol Phys. 2010;77:119-24.
17. James N, Hussain SA, Hall E, et al. Results of a 2×2 phase III randomized trial of synchronous chemo-radiotherapy compared to radiotherapy alone and standard versus reduced high dose volume radiotherapy in muscle invasive bladder cancer ASTRO; November 2010; San Diego. 2010.
18. Hoskin PJ, Rojas AM, Bentzen SM Saunders MI. Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma. J Clin Oncol. 2010;28:4912-8.
19. Henningsohn L, Steven K, Kallestrup EB Steineck G. Distressful symptoms and well-being after radical cystectomy and orthotopic bladder substitution compared with a matched control population. J Urol. 2002;168:168-74.
20. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet. 2003;361:1927-34.
21. Botteman MF, Pashos CL, Redaelli A, et al. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics. 2003;21:1315-30.
22. Bryan RT, Guenther U, Wei W, et al. Detection and staging of bladder cancer by 'OMIC' analysis of urine. BJUI. 2011;108:7-8.
23. Bryan RT, Wei W, Shimwell NJ, et al. Assessment of high-throughput high-resolution MALDI-TOF-MS of urinary peptides for the detection of muscle-invasive bladder cancer. Proteomics Clin Appl. 2011 Aug 1. [Epub ahead of print.]
24. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49:466-5; discussion 75-7.
25. Leary RJ, Kinde I, Diehl F, et al. Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med. 2010;2:20ra14.
26. Bryan RT. Bladder cancer and cancer stem cells: basic science and implications for therapy. ScientificWorldJournal. 2011;11:1187-94.
27. Zeegers MP, Bryan RT, Langford C, et al. The West Midlands Bladder Cancer Prognosis Programme: rationale and design. BJU Int. 2009;105:784-8.